Clinical Trial

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-04
Trial Details
NCT Number NCT07483554
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Enrollment 389 participants
Start Date 2026-04-20
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03